Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 36 of the 62 sources its claims cite were checked for support.

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

Open access
Ward, Kristen, Citrome, Leslie · 2019 · Neuropsychiatric Disease and Treatment

Abstract

The purpose of this review is to describe the available data for brexpiprazole in the maintenance treatment of schizophrenia. This objective was completed by searching the databases PubMed, Embase, and ClinicalTrials.gov to identify relevant study results presented as papers or abstracts. In summary, brexpiprazole is a new agent in the D 2 partial agonist class that has a unique receptor-binding profile, based in part on high affinity for serotonin 5HT 1A and 5HT 2A receptors, paired with lower intrinsic activity at dopamine D 2 receptors. The average dose used in efficacy and safety studies for the maintenance treatment of schizophrenia ranged from 3.0 and 3.1 mg in the open-label safety studies to 3.6 mg in the double-blind randomized relapse-prevention study. Highlights from the 52-week double-blind placebo-controlled relapse-prevention trial evidenced rates of relapse in the brexpiprazole group of 13.5% vs 38.5% in the placebo group (number needed to treat 4, 95% CI 3–8; P <0.0001). Safety data indicate that brexpiprazole is tolerated well, with rates of discontinuation due to treatment-emergent adverse events that ranged from 5.2% of those taking brexpiprazole in the double-blind maintenance phase of the relapse-prevention trial to 15.3% in a 52-week open-label safety study. In the available trials, there were relatively low rates of akathisia, and the degree of weight gain was similar to that seen in studies with aripiprazole for the treatment of schizophrenia. Positive and Negative Syndrome Scale scores also remained relatively stable in the open-label safety studies. Available data indicate that brexpiprazole is an effective agent for the maintenance treatment of schizophrenia that is overall well tolerated. Keywords: akathisia, weight gain, second-generation antipsychotics, atypical antipsychotics, relapse prevention

Overview

CoChat Summary

TL;DR

This evidence-based review summarizes brexpiprazole for maintenance treatment of schizophrenia in adults, focusing on three 52-week phase III trials and related analyses. It concludes that brexpiprazole is effective for relapse prevention and generally well tolerated, with low akathisia and weight gain similar to aripiprazole.

Key findings

  • In the 52-week randomized, double-blind, placebo-controlled relapse-prevention trial, impending relapse occurred in 13.5% of brexpiprazole-treated patients vs 38.5% with placebo (number needed to treat 4, 95% CI 3–8; P<0.0001); time to impending relapse favored brexpiprazole (HR 0.292, 95% CI 0.156–0.548, P<0.0001).
  • Discontinuation due to treatment-emergent adverse events ranged from 5.2% in the double-blind maintenance phase of the relapse-prevention trial to 15.3% in a 52-week open-label safety study.
  • Akathisia rates were relatively low, and weight gain appeared similar to aripiprazole; by week 52, average weight gain was 3.2 kg with brexpiprazole vs 4.0 kg with aripiprazole, and weight increase ≥7% was 18.6% vs 25.3%, respectively.
  • In open-label safety studies, Positive and Negative Syndrome Scale scores remained relatively stable; average daily doses were 3.0–3.1 mg in open-label studies and 3.6 mg in the double-blind relapse-prevention study.

Methods

  • Narrative evidence-based review; PubMed, Embase, and ClinicalTrials.gov were searched for brexpiprazole maintenance-treatment study results, with the first search on September 26, 2018, and additional entries identified through November 4, 2018.
  • The search identified 60 PubMed entries, 152 Embase entries, and 35 ClinicalTrials.gov trials, including three 52-week phase III trials: two open-label flexible-dose safety studies and one randomized, double-blind, placebo-controlled relapse-prevention trial.
  • The review summarizes pharmacology, pharmacokinetics, long-term efficacy and safety data, and comparative/cost/titration analyses.

Limitations

  • The paper states limitations of the long-term investigations: lack of an active comparator, strict inclusion criteria not necessarily reflective of clinical settings, and possible enrichment of the study population by including patients from previous phase III trials who tolerated brexpiprazole.
  • The paper notes very few safety data in patients with schizophrenia >65 years old, limited direct comparisons with other antipsychotics or in patients with comorbid psychiatric disease/medication use, and that tablets are the only available dosage form.
  • Evident from the text: the relapse-prevention trial was terminated early after the first interim analysis, and only 23 participants received brexpiprazole through week 52 in that trial, limiting long-term exposure data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/ndt.s169369

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

34 Valid · 1 Not valid · 22 Not checked · 40 Own results and interpretations

43 more claims · 7 with their cited sources checked

Create a free account to see all 97 claims and to verify the 8 references still open.

See all claims — free account
  • It may state two separate claims as one. 40
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Cited by

See all 181

Metadata

Authors
Ward, K., & Citrome, L.
Affiliations
  • University of Michigan (US)
  • New York Medical College (US)
Corresponding author
Citrome, Leslie
Venue
Neuropsychiatric Disease and Treatment
Published
2019-01
Volume
Volume 15
Pages
247-257
ISSN
  • 1176-6328 (ISSN-L)
  • 1178-2021
OpenAlex
W2910694408
Cited by
181
References
27
Citations by year
2026: 1 · 2025: 1 · 2024: 5 · 2023: 2 · 2022: 1 · 2021: 6 · 2020: 163 · 2019: 1
FWCI
34.00
Type
journal article
Language
en
Open access
Locations
  • Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Touro Scholar (Touro College) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
University of Michigan
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
brexpiprazole, schizophrenia, maintenance therapy, relapse prevention, dopamine D2 receptor, atypical antipsychotics, akathisia, weight gain, treatment-emergent adverse events, antipsychotic efficacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.